BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $806 | -22.2% | 11,840 | -6.7% | 0.00% | -20.0% |
| Q2 2023 | $1,036 | +30.2% | 12,689 | +18.2% | 0.01% | +25.0% |
| Q1 2023 | $796 | -18.3% | 10,733 | -8.7% | 0.00% | -20.0% |
| Q4 2022 | $974 | -99.7% | 11,757 | +951.6% | 0.01% | +150.0% |
| Q3 2022 | $318,000 | -16.8% | 1,118 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $382,000 | -69.2% | 1,101 | -61.6% | 0.00% | -66.7% |
| Q1 2022 | $1,241,000 | -34.9% | 2,866 | -22.2% | 0.01% | -33.3% |
| Q4 2021 | $1,905,000 | +23.2% | 3,682 | +15.4% | 0.01% | +12.5% |
| Q3 2021 | $1,546,000 | +50.0% | 3,191 | +39.4% | 0.01% | +60.0% |
| Q2 2021 | $1,031,000 | -13.8% | 2,289 | -26.9% | 0.01% | -16.7% |
| Q1 2021 | $1,196,000 | +21.5% | 3,131 | +1.0% | 0.01% | 0.0% |
| Q4 2020 | $984,000 | +73.2% | 3,100 | +35.2% | 0.01% | +50.0% |
| Q3 2020 | $568,000 | -91.6% | 2,293 | -91.1% | 0.00% | -92.2% |
| Q2 2020 | $6,782,000 | +38.4% | 25,682 | -0.6% | 0.05% | +8.5% |
| Q1 2020 | $4,900,000 | -5.4% | 25,842 | +9.6% | 0.05% | +17.5% |
| Q4 2019 | $5,177,000 | +646.0% | 23,585 | +564.9% | 0.04% | +566.7% |
| Q3 2019 | $694,000 | -6.1% | 3,547 | +0.1% | 0.01% | -14.3% |
| Q2 2019 | $739,000 | +6.8% | 3,544 | +1.8% | 0.01% | 0.0% |
| Q1 2019 | $692,000 | +31.1% | 3,483 | -4.5% | 0.01% | +16.7% |
| Q4 2018 | $528,000 | -32.0% | 3,647 | -4.1% | 0.01% | -14.3% |
| Q3 2018 | $776,000 | +44.2% | 3,801 | +4.6% | 0.01% | +16.7% |
| Q2 2018 | $538,000 | -5.4% | 3,635 | -3.5% | 0.01% | 0.0% |
| Q1 2018 | $569,000 | +16.6% | 3,765 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $488,000 | +6.6% | 3,765 | -0.6% | 0.01% | 0.0% |
| Q3 2017 | $458,000 | -2.3% | 3,787 | -5.1% | 0.01% | -14.3% |
| Q2 2017 | $469,000 | +26.1% | 3,992 | +9.0% | 0.01% | +16.7% |
| Q1 2017 | $372,000 | -0.8% | 3,664 | +0.5% | 0.01% | -14.3% |
| Q4 2016 | $375,000 | -5.8% | 3,644 | +0.2% | 0.01% | 0.0% |
| Q3 2016 | $398,000 | -3.4% | 3,636 | -0.6% | 0.01% | -22.2% |
| Q2 2016 | $412,000 | +23.7% | 3,657 | +3.8% | 0.01% | +12.5% |
| Q1 2016 | $333,000 | +5.4% | 3,524 | +0.3% | 0.01% | +14.3% |
| Q4 2015 | $316,000 | -2.5% | 3,515 | +0.3% | 0.01% | -22.2% |
| Q3 2015 | $324,000 | – | 3,504 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |